Gilead Sciences, Inc. $GILD Stock: AMF Tjanstepension AB Lowers Holdings

Key Points

• AMF Tjanstepension AB cut its Gilead stake by 96.1%. The fund sold 521,261 shares during the third quarter and retained 21,001 shares valued at approximately $3.13 million.
• Analyst sentiment remains broadly positive. Twenty-three analysts rate Gilead a Buy and six rate it a Hold, producing a “Moderate Buy” consensus and an average price target of $159.63.
• Growth catalysts and risks remain in focus. Gilead’s oncology collaboration with BioNTech and upcoming liver-disease data could support expansion beyond HIV, while clinical execution, valuation and recent insider selling remain potential concerns.

AMF Tjanstepension AB cut its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 96.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,001 shares of the biopharmaceutical company's stock after selling 521,261 shares during the quarter. AMF Tjanstepension AB's holdings in Gilead Sciences were worth $3,130,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in GILD. PFS Partners LLC increased its holdings in Gilead Sciences by 101.1% in the 3rd quarter. PFS Partners LLC now owns 191 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 96 shares during the period. Persistent Asset Partners Ltd purchased a new position in Gilead Sciences during the 2nd quarter worth approximately $25,000. Kimelman & Baird LLC purchased a new position in Gilead Sciences during the 2nd quarter worth approximately $25,000. Toth Financial Advisory Corp lifted its stake in Gilead Sciences by 85.5% during the 3rd quarter. Toth Financial Advisory Corp now owns 217 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 100 shares during the period. Finally, Trellis Wealth Advisors LLC acquired a new stake in Gilead Sciences during the 3rd quarter valued at approximately $33,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Earnings expectations are supportive. Analysts expect Gilead to potentially beat its upcoming third-quarter estimates, supported by favorable estimate revisions and the company’s history of exceeding consensus forecasts. A strong report or upbeat outlook could reinforce the recent momentum. Gilead Sciences Expected to Beat Earnings Estimates
• Positive Sentiment: Oncology pipeline receives a potential boost. Gilead and BioNTech entered a clinical-trial collaboration and supply agreement to test BioNTech’s pumitamig with Gilead’s TROP2-directed antibody-drug conjugate sacituzumab govitecan in the Phase 3 ROSETTA Breast-01 trial for advanced triple-negative breast cancer. Success could expand the commercial opportunity for Trodelvy and support Gilead’s strategy of building growth beyond HIV. BioNTech and Gilead to Test Drug Combination
• Positive Sentiment: Investors are highlighting longer-term growth drivers. A bullish investment thesis points to Gilead’s durable HIV franchise, oncology expansion and potential for pipeline-led growth without relying primarily on acquisitions. Bank of America also reportedly expects additional upside, adding to the positive analyst narrative. Bank of America Analyst Expects Gilead Stock to Rise
• Neutral Sentiment: Upcoming liver-disease data could provide another catalyst. Gilead plans to present clinical and real-world evidence on primary biliary cholangitis and chronic hepatitis delta at The Liver Meeting in November. The data may support confidence in long-term treatment durability and disease management, although the investment impact will depend on the results. Gilead to Present New Liver-Disease Data
• Negative Sentiment: Valuation and clinical execution remain risks. The shares recently declined during one session despite broader market gains, indicating some sensitivity to profit-taking or company-specific concerns. The BioNTech program is still dependent on Phase 3 results, while the stock’s proximity to its high leaves less room for disappointment if earnings or pipeline data fall short. Gilead Stock Drops Despite Market Gains

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $145.02, for a total transaction of $725,100.00. Following the transaction, the director owned 10,066 shares in the company, valued at approximately $1,459,771.32. This represents a 33.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Anthony Welters sold 18,000 shares of the business's stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $148.62, for a total value of $2,675,160.00. Following the completion of the sale, the director owned 12,894 shares of the company's stock, valued at $1,916,306.28. This trade represents a 58.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 111,000 shares of company stock worth $15,877,860 over the last quarter. Company insiders own 0.30% of the company's stock.

Analyst Ratings Changes

Several research firms have recently commented on GILD. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $155.00 price objective on shares of Gilead Sciences in a report on Thursday, October 8th. Wall Street Zen raised shares of Gilead Sciences from a "hold" rating to a "buy" rating in a report on Saturday, September 19th. Truist Financial raised their target price on shares of Gilead Sciences from $150.00 to $158.00 and gave the stock a "buy" rating in a report on Wednesday, October 7th. Leerink Partners downgraded shares of Gilead Sciences from an "outperform" rating to a "market perform" rating and decreased their target price for the company from $146.00 to $127.00 in a research report on Tuesday, July 21st. Finally, JPMorgan Chase & Co. upped their price target on shares of Gilead Sciences from $160.00 to $170.00 and gave the company an "overweight" rating in a report on Wednesday, October 7th. Twenty-three research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $159.63.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD opened at $157.19 on Friday. Gilead Sciences, Inc. has a 12 month low of $114.02 and a 12 month high of $160.51. The firm's 50 day simple moving average is $148.74 and its 200-day simple moving average is $137.72. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The firm had revenue of $7.80 billion during the quarter, compared to analyst estimates of $7.40 billion. During the same period in the previous year, the firm earned $2.01 EPS. The business's quarterly revenue was up 10.6% on a year-over-year basis. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post -0.47 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th were paid a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.1%. The ex-dividend date was Tuesday, September 15th. Gilead Sciences's payout ratio is currently -122.85%.

Gilead Sciences Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.